Targeting EBV gp42 for nasopharyngeal carcinoma prevention
Molecular Therapy · 2025-07 · 33 (7) · 2987-2989
DOI: 10.1016/j.ymthe.2025.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025-07. Verfasst von Cong Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Noncommunicable Chronic Disease-National Science and Technology Major Project, National Natural Science Foundation of China, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)-associated malignancy, remains a significant public health burden in endemic regions such as southern China.1 While early detection through serologic biomarkers has improved outcomes, the development of preventive strategies remains a challenge. Recent work by Kong et al. highlights the protective role of high gp42-immunoglobulin (Ig)G titers against NPC risk, offering new insights into EBV immunobiology and opportunities for vaccine design.
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center…
Förderung
- Noncommunicable Chronic Disease-National Science and Technology Major Project
- National Natural Science Foundation of China
- National Key Research and Development Program of China Stem Cell and Translational Research
- National Key Research and Development Program of China
- China Postdoctoral Science Foundation
Zitieren
APA
Sun, C., Zhang, L. L., & Zeng, M. S. (2025). Targeting EBV gp42 for nasopharyngeal carcinoma prevention. Molecular Therapy, 33(7), 2987-2989. https://doi.org/10.1016/j.ymthe.2025.06.005
Vancouver
Sun C, Zhang LL, Zeng MS. Targeting EBV gp42 for nasopharyngeal carcinoma prevention. Molecular Therapy. 2025;33(7):2987-2989. doi:10.1016/j.ymthe.2025.06.005
BibTeX
@article{Sun2025,
author = {Sun, Cong and Zhang, Le-Le and Zeng, Mu-Sheng},
title = {Targeting EBV gp42 for nasopharyngeal carcinoma prevention},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {7},
pages = {2987--2989},
doi = {10.1016/j.ymthe.2025.06.005}
}
EUVIMED